Biotech Scan
Biotech Scan
Novo Nordisk broke this week, and the desk has a real reason for it: the company's own 2030 growth targets, announced September 20, read as insufficient against rising GLP-1 competition and looming patent expirations, and the stock fell about 6% that day. $NVO now sits at RSI 27.5, down 8.49% on the week and 35.89% on the year — the cut's clearest structural breakdown. $NKTR joined it from the other direction: RSI fell from 38.7 to 24.6 with no driver on the desk's record, the first name to sit in outright capitulation since $RARE vacated the band two scans ago. At the other end, the top of the cohort kept extending: $MRNA (RSI 71.9) and $ILMN (71.5) are both now in the near-overbought band the desk's own stretch screen flagged today, and $BIIB jumped from RSI 50.4 to 63.4 on a 5.33% week with nothing in its news file to explain it.
Data as-of the 2026-09-23 close (Wednesday's settled session) — every name in this cut carries a fresh bar; universe unchanged at 39 tickers.
Quick Snapshot
| Signal | Reading |
|---|---|
| Overall | 🟡 A cohort splitting further apart — a real, sourced breakdown in $NVO, an unexplained new capitulation print in $NKTR, and the top of the board pushing into stretched territory on thin-to-normal volume |
| Leaders | $MRNA (RSI 71.9, +25.06% on the week, +606.13% on the year); $ILMN (71.5, +11.55% on the week, +157% on the year, but on only 0.62x average volume); $TMO (71.5, +2.6% on the week, trend intact); $BIIB (63.4, +5.33% on the week, no news receipt covering the move) |
| Laggards | $NKTR (24.6, cratered from 38.7, no cause found); $NVO (27.5, -8.49% on the week on a sourced 2030-guidance disappointment); $IMVT (28.5, down from 36.1, but still 10% above its 200-day with a +131.81% year — a pullback, not a breakdown) |
| Key insight | $NVO is the one name in this cut with an actual corpus-sourced cause for its break; $NKTR's identical-looking capitulation print has none — treat the two very differently |
| Caveat | $NKTR's news file was last pulled June 21 and predates this move by three months; that silence is a coverage gap, not evidence nothing happened |
What's Going On
The cohort's bottom got a real story this week. Novo Nordisk laid out 2030 growth targets on September 20 that investors read as inadequate given rising GLP-1 competition and approaching patent cliffs, and the stock dropped roughly 6% that session (Investing.com, via the desk's news pull). A day later Wegovy picked up a China approval for MASH, a genuine positive, but it didn't offset the guidance reaction: $NVO closed the week at $38.17, RSI 27.5, down 8.49% on the week, 18.65% on the month and 35.89% on the year, now 17.1% below its 200-day. This is the rare case in this cut where a name's break has a corpus receipt behind it rather than an open question.
$NKTR is the opposite case. RSI fell from 38.7 to 24.6 — the cut's only capitulation print — on a 14.43% weekly decline that has nothing behind it on the desk's record. Its news file was last pulled June 21, three months before this move, so the silence there is a coverage gap, not an answer. The break also changed $NKTR's structural read: a week ago it passed the long test with a positive year and a price above its 200-day; it now sits 11.9% below that average with a -3.26% year, a genuine trend failure rather than a bounce-worthy dip.
The top of the cohort kept running, and two of those names are the exact ones the desk's own stretch screen flagged today. $MRNA closed at $182.11, RSI 71.9, up 25.06% on the week and 606.13% on the year, on volume close to its average (0.96x) — an extreme multi-quarter move continuing rather than reversing. $ILMN closed at $255.38, RSI 71.5, up 11.55% on the week and 157% on the year, but on only 0.62x its average volume — the same stretch, thinner participation behind it. $TMO also crossed into the same band at 71.5. None of these three is a new signal; each is the continuation of a trend this scan has called extended for multiple weeks running.
$BIIB is the week's quieter surprise: RSI jumped from 50.4 to 63.4 on a 5.33% gain, and the desk's news file — last pulled September 16 — has nothing dated to this move. $IMVT deserves the opposite read from what its falling RSI suggests: it dropped from 36.1 to 28.5 on a 5.06% weekly decline, but it remains 10% above its 200-day with a 131.81% year and a +116.04 alpha — a deep pullback inside an intact, strongly working trend, not a breakdown, even though its RSI now sits below several names the desk is calling broken.
What Changed Since Prior Scan (2026-09-18)
- $NVO broke on a sourced cause. RSI 41.3 → 27.5, price $43.24 → $38.17 (-8.49% on the week), on 2030 growth targets the market read as underwhelming (announced September 20) — the first clean corpus-sourced breakdown this scan has carried in weeks.
- $NKTR fell into capitulation with no cause found. RSI 38.7 → 24.6, price $67.10 → $57.66; its long-test read flipped from passing to failing — year +14.2% → -3.26%, vs. its 200-day +2.7% → -11.9%. News file predates the move by three months.
- $MRNA and $ILMN both crossed into the near-overbought band. MRNA: RSI 63.3 → 71.9, +25.06% on the week. ILMN: RSI 65.7 → 71.5, +11.55% on the week, but on only 0.62x average volume.
- $BIIB jumped 13 RSI points with no driver on the desk's record. RSI 50.4 → 63.4, price $215.50 → $227.53 (+5.33%).
- $AMGN exited the oversold band entirely. RSI 39.7 → 51.9, price $385.65 → $406.09 (+5.30%), continuing its recovery from two scans ago.
- $PTGX and $BMRN both slid into the oversold band. PTGX: RSI 45.2 → 39.0, -2.90% on the week. BMRN: RSI 45.7 → 39.3, -3.89%. Both still pass the long test (positive years, above their 200-day) — pullbacks, not breakdowns.
- $LEGN and $RARE both climbed out of oversold. LEGN: RSI 34.1 → 41.2, +8.53% on the week. RARE: RSI 28.1 → 32.6, +15.53% — but RARE is still 40.1% below its 200-day with a -47.61% year; the trend has not turned.
- $IMVT dropped deeper into oversold inside an intact trend. RSI 36.1 → 28.5, -5.06% on the week — still 10% above its 200-day with a +131.81% year.
- The capitulation band gained its first name since $RARE vacated it two scans ago. $NKTR (24.6) is now the sole occupant.
- No stale bars this scan — every name carries a fresh 2026-09-23 close. Universe unchanged at 39 tickers.
How To Read The Board
RSI measures how stretched a name is over the last fourteen sessions: under 30 is oversold, over 70 near-overbought. The one-year return and the distance to the 200-day average separate a pullback from a breakdown, and this scan is a clean illustration of why that matters more than the RSI reading itself. $NVO and $IMVT both fell into oversold territory this week, but $NVO is now 17.1% below its 200-day with a -35.89% year (a genuine break, and one with a sourced cause) while $IMVT sits 10% above its 200-day with a +131.81% year (a deep pullback in a trend that has worked for a year). $NKTR's capitulation print looks the same as $NVO's on RSI alone but carries no established cause at all — the two names should not be read the same way just because their charts rhyme this week.
Price Table
| Stock | Price | RSI | SMA20 | vs SMA20 | 7D% | 30D% | 1Y% | vs SMA200 | Signal |
|---|---|---|---|---|---|---|---|---|---|
| NKTR | $57.66 | 24.6 | $69.99 | -17.6% | -14.4% | -21.8% | -3.3% | -11.9% | 🔴 New capitulation print, cause unknown |
| IONS | $43.93 | 27.3 | $53.83 | -18.4% | -2.0% | -29.2% | -29.8% | -38.7% | 🔴 Still the cut's deepest structural break |
| NVO | $38.17 | 27.5 | $43.93 | -13.1% | -8.5% | -18.7% | -35.9% | -17.1% | 🔴 Broke on underwhelming 2030 targets |
| IMVT | $34.54 | 28.5 | $38.78 | -10.9% | -5.1% | -20.3% | +131.8% | +10.0% | 🟡 Deep pullback, trend firmly intact |
| RARE | $14.88 | 32.6 | $17.88 | -16.8% | +15.5% | -42.2% | -47.6% | -40.1% | 🔴 Bouncing, trend still broken |
| COGT | $31.41 | 33.6 | $33.94 | -7.5% | -3.5% | -13.3% | +142.7% | -14.3% | 🟡 Big run digesting below its 200-day |
| PTGX | $138.70 | 39.0 | $145.70 | -4.8% | -2.9% | -10.4% | +113.2% | +26.6% | 🟡 New to oversold, trend intact |
| BMRN | $62.21 | 39.3 | $65.00 | -4.3% | -3.9% | -4.4% | +16.5% | +6.4% | 🟡 New to oversold, trend intact |
| BEAM | $24.37 | 40.5 | $26.64 | -8.5% | +5.5% | -14.0% | +2.7% | -14.7% | 🔴 Flat year, below its 200-day |
| LEGN | $18.45 | 41.2 | $19.52 | -5.5% | +8.5% | -11.9% | -44.0% | -18.3% | 🔴 Exited oversold, trend still broken |
| MDT | $89.30 | 42.6 | $91.95 | -2.9% | -3.6% | -3.9% | -6.0% | +0.2% | 🟡 Flat year, sitting on its 200-day |
| EDIT | $2.69 | 43.7 | $2.91 | -7.6% | -0.7% | -10.3% | -10.6% | +2.1% | 🟡 Negative year, above its 200-day |
| XBI | $155.20 | 44.2 | $160.44 | -3.3% | +0.7% | -5.5% | +60.4% | +12.7% | 🟡 Cohort fund |
| SRPT | $18.95 | 44.3 | $20.95 | -9.5% | -4.1% | +4.5% | +5.7% | -1.5% | 🟡 Flat, trend barely intact |
| LLY | $1,150.99 | 46.6 | $1,150.82 | 0.0% | +1.2% | -7.7% | +54.1% | +7.7% | 🟡 Pullback, trend intact |
| VRTX | $516.34 | 46.8 | $529.18 | -2.4% | +0.6% | -5.7% | +36.0% | +9.6% | 🟡 Pullback, trend intact |
| KYMR | $115.47 | 47.9 | $117.72 | -1.9% | -0.7% | -4.6% | +127.0% | +25.3% | 🟢 Healthy, pulled back this week |
| BNTX | $98.46 | 48.5 | $100.67 | -2.2% | +2.7% | -12.7% | +0.2% | +0.9% | 🟡 Flat year, at its 200-day |
| IBBQ | $34.76 | 49.0 | $35.28 | -1.5% | +1.2% | -3.7% | +45.2% | +13.2% | 🟢 Cohort fund |
| ALNY | $246.51 | 49.9 | $248.35 | -0.7% | +3.0% | +4.5% | -45.8% | -20.2% | 🔴 Breakdown |
| NTLA | $12.33 | 50.4 | $12.39 | -0.5% | +7.3% | -1.8% | -27.8% | -3.4% | 🔴 Negative year, below its 200-day |
| INCY | $124.64 | 50.6 | $125.25 | -0.5% | -0.1% | -2.6% | +47.4% | +17.6% | 🟢 Healthy trend |
| CRSP | $55.76 | 51.2 | $55.78 | 0.0% | +6.8% | -2.3% | -8.2% | +4.5% | 🟡 Negative year despite the RSI |
| IBB | $206.60 | 51.6 | $208.10 | -0.7% | +2.1% | -2.8% | +45.0% | +15.0% | 🟢 Cohort fund |
| AMGN | $406.09 | 51.9 | $407.73 | -0.4% | +7.9% | -8.5% | +41.6% | +12.4% | 🟢 Exited oversold, healthy trend |
| DXCM | $87.73 | 52.4 | $87.79 | -0.1% | +0.5% | -3.7% | +28.6% | +21.2% | 🟢 Cooled off, trend intact |
| REGN | $801.82 | 53.1 | $803.81 | -0.2% | +3.5% | -3.2% | +41.2% | +9.1% | 🟢 Healthy pullback |
| RXRX | $3.70 | 55.6 | $3.47 | +6.6% | +16.0% | +13.9% | -23.1% | +2.9% | 🟡 Cooled off, still negative year |
| ABBV | $265.08 | 60.2 | $259.66 | +2.1% | +1.0% | +0.2% | +19.1% | +15.2% | 🟢 Healthy trend |
| IQV | $267.86 | 61.1 | $264.58 | +1.2% | -0.4% | +2.9% | +43.7% | +31.1% | 🟢 Healthy trend |
| DNA | $8.58 | 61.3 | $7.30 | +17.5% | +21.5% | +26.5% | -30.5% | +4.0% | 🔴 Bounce extending inside a broken trend |
| GILD | $151.37 | 61.9 | $148.38 | +2.0% | +2.5% | +3.2% | +32.3% | +11.5% | 🟢 Healthy trend |
| ISRGE | $398.30 | 62.0 | $375.70 | +6.0% | +4.2% | +6.6% | -11.0% | -12.0% | 🔴 Bounce, long trend still broken |
| BIIB | $227.53 | 63.4 | $218.68 | +4.0% | +5.3% | +4.3% | +63.3% | +17.6% | 🟢 Big jump, cause unknown |
| DHR | $221.56 | 66.3 | $210.54 | +5.2% | +6.3% | +3.0% | +16.8% | +9.8% | 🟢 Breakout, healthy trend |
| A | $165.32 | 69.5 | $153.10 | +8.0% | +7.6% | +7.8% | +31.3% | +25.4% | 🟢 Extended, healthy trend |
| ILMN | $255.38 | 71.5 | $222.58 | +14.7% | +11.6% | +14.4% | +157.0% | +61.8% | 🟠 Extreme extension, thin volume (0.62x) |
| TMO | $665.30 | 71.5 | $628.12 | +5.9% | +2.6% | +5.8% | +41.6% | +23.4% | 🟠 Near-overbought, trend intact |
| MRNA | $182.11 | 71.9 | $150.63 | +20.9% | +25.1% | +31.1% | +606.1% | +191.1% | 🟠 Extreme multi-quarter move, continuing |
Tier Analysis
Capitulation (RSI < 25)
$NKTR (24.6) — new this scan, no established cause. Its long-test read flipped this week from passing to failing (now -11.9% below its 200-day with a -3.26% year).
Oversold (RSI 25-40)
$IONS (27.3), $NVO (27.5), $IMVT (28.5), $RARE (32.6), $COGT (33.6), $PTGX (39.0), $BMRN (39.3) — seven names. Only $IMVT (+131.81% year, +10% vs. its 200-day), $COGT (+142.74% year, though below its 200-day) and the newcomers $PTGX and $BMRN pass or partially pass the long test — those are pullbacks. $IONS, $NVO and $RARE fail both legs outright and are breakdowns; $NVO is the one with a sourced cause.
Neutral to strong (RSI 40+)
- Structurally broken (below the 200-day with a flat-to-negative year): $BEAM, $LEGN, $ALNY, $NTLA, $ISRG, $DNA. A strong week here is a bounce — $DNA rose 21.53% and $ISRG 4.19% without either number improving.
- Negative year but holding the 200-day: $EDIT, $MDT, $CRSP, $RXRX, $BNTX — the ambiguous middle.
- Pullback, trend intact: $XBI, $SRPT, $LLY, $VRTX, $KYMR, $IBBQ, $IBB, $ABBV, $IQV, $GILD, $REGN — all above the 200-day with a positive year.
- Healthy and working: $INCY, $AMGN, $DXCM, $BIIB, $DHR, $A.
- Near-overbought, trend intact: $ILMN (thin volume), $TMO.
- Extreme move, high variance: $MRNA — up 606.1% on the year, continuing rather than reversing.
Entry Zones
| Stock | Price | Zone | RSI | 1Y% | Conditions |
|---|---|---|---|---|---|
| IMVT | $34.54 | Watch $38.78 (its 20-day); $26.96 the shelf below | 28.5 | +131.8% | Deep pullback with the long trend firmly intact, 10% above its 200-day; a reclaim of the 20-day is the confirmation |
| PTGX | $138.70 | $101.26 (a prior support shelf) to $145.70 (its 20-day) | 39.0 | +113.2% | New to oversold with a strong trend still intact, 26.6% above its 200-day |
| BMRN | $62.21 | $56.05 (a prior support shelf) | 39.3 | +16.5% | New to oversold, long trend intact; the shelf is the level that matters |
| NVO | $38.17 | $36.93 (a prior support shelf) | 27.5 | -35.9% | Broke on a sourced cause with no confirmed floor; the shelf below is the next test, not an entry signal yet |
| NKTR | $57.66 | No support shelf identified | 24.6 | -3.3% | Deepest print in the cut with no established cause and no confirmed floor — a watch item, not an entry |
Action Matrix
| Stock | Signal | Action | Notes |
|---|---|---|---|
| INCY, AMGN, DXCM, BIIB, DHR, A, ABBV, IQV, GILD | 🟢 | 🔒 Hold | Above the 200-day with a positive year and positive alpha; $A and $DHR are the most extended of the group |
| XBI, SRPT, LLY, VRTX, KYMR, IBBQ, IBB, REGN | 🟡 | 📈 Accumulate | Pullbacks inside intact trends — below their 20-day, above their 200-day, positive years |
| IMVT, PTGX, BMRN, COGT | 🟡 | 🔍 Watch | Newly oversold or digesting with the long trend intact; confirm a floor before adding |
| EDIT, MDT, CRSP, RXRX, BNTX | 🟡 | 🔍 Watch | Negative-to-flat years above their long averages — the ambiguous middle |
| ILMN, TMO | 🟠 | ⚠️ Don't chase | Trends working, prices stretched; $ILMN's move is on only 0.62x average volume |
| MRNA | 🟠 | ⚠️ Don't chase | Extreme multi-quarter move continuing; up 606.1% on the year |
| NVO, NKTR, IONS, RARE, LEGN, BEAM, ALNY, NTLA, ISRG, DNA | 🔴 | ❌ Avoid | Below the 200-day with a flat-to-negative year; $NVO has a sourced cause, $NKTR does not |
What To Watch Next
- $NVO has a real, dated cause for its break — underwhelming 2030 growth targets announced September 20. The question now is whether the next print (or the China MASH approval already on the record) stabilizes the name above $36.93, its nearest support shelf, or whether the guidance disappointment keeps compounding.
- $NKTR fell into capitulation with nothing on the desk's record explaining it; its news file predates the move by three months. Does a driver surface on the next pull, or does this stay the cut's one unexplained breakdown?
- $MRNA and $ILMN are both now inside the near-overbought band the desk's own stretch screen flagged today. $ILMN's move is happening on only 0.62x average volume — worth watching whether volume confirms the breakout or the move fades on thin participation.
- $BIIB jumped 13 RSI points on a 5.33% week with no news receipt covering it. Does a filing or transcript surface, or does this stay an unexplained gain inside an already-healthy trend?
- $IMVT and $NVO both fell into oversold territory this week, but one is a deep pullback in a trend up 131.81% over the year and the other is a genuine, sourced breakdown. Watch whether the market keeps treating them differently or lumps them together on RSI alone.
Sources
- Tape data (price, RSI, moving averages, returns, long-horizon fields): pre-computed summaries as of the 2026-09-23 close — biotech-scan.
- $NVO 2030-guidance reaction and China MASH approval: latest (pulled 2026-09-22; articles dated 2026-09-20 and 2026-09-22).
- News checks with nothing on this week's move: latest (pulled 2026-06-21, predates the move by three months),
BIIB(pulled 2026-09-16, nothing newer than September 3),AMGN(pulled 2026-09-22, newest article dated September 10),MRNA(pulled 2026-09-22, aggregator pages only),ILMN(pulled 2026-09-22, newest article September 18). Event recordresearch/stock-events/checked for the 2026-09-18 to 2026-09-23 window: only ABVX, AIR, SFIX, GIS and MU earnings are filed, none in this cut. - Prior scan for comparison: 2026-09-18-biotech-scan.
Related
10 eventsNo direct external sources are attached to this read.